Table 5.

Proportional hazards regression assessing whether an increase in ANCA is associated with relapse (Truncated after 1-year).

	HR	95% C.I.	p	c-index
All subjects
Any flare	1.57	0.81, 3.05	0.156	0.55
Severe flare	5.45	1.83, 16.19	0.002	0.65
According to treatment
Cyclophosphamide
Any flare	1.64	0.50, 5.41	0.418	0.52
Severe flare	8.04	0.97, 66.47	0.053	0.62
Rituximab
Any flare	1.59	0.65, 3.86	0.307	0.54
Severe flare	5.58	1.11, 28.04	0.037	0.64
According to renal involvement
Without renal involvement
Any flare	2.67	0.83, 8.56	0.100	0.60
Severe flare	3.04	0.80, 11.54	0.103	0.63
With renal involvement
Any flare	1.09	0.47, 2.54	0.844	0.50
Severe flare	10.32	1.32, 80.97	0.026	0.67
According to baseline capillaritis
Without capillaritis
Any flare	4.74	0.53, 42.52	0.165	0.63
Severe flare	4.38	0.47, 40.42	0.193	0.64
With capillaritis
Any flare	1.23	0.60, 2.54	0.573	0.52
Severe flare	5.43	1.55, 19.11	0.008	0.66
According to baseline DAH
Without DAH
Any flare	0.96	0.45, 2.06	0.918	0.50
Severe flare	2.87	0.91, 9.06	0.072	0.61
With DAH
Any flare	5.24	1.13, 24.26	0.034	0.68
Severe flare	∞	4.21, ∞	<0.001	0.74
According to new vs. relapsing
Relapsing disease
Any flare	1.24	0.54, 2.83	0.613	0.51
Severe flare	6.62	1.43, 30.79	0.016	0.65
New disease
Any flare	2.51	0.68, 9.27	0.166	0.59
Severe flare	7.18	0.89, 58.03	0.065	0.66
Any granulomatous disease
Any flare	1.89	0.81, 4.24	0.143	0.56
Severe flare	7.22	1.64, 31.75	0.009	0.64
Granulomatous disease only
Any flare	2.88	0.28, 30.00	0.375	0.59
Severe flare	2.88	0.28, 30.00	0.375	0.61